Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites

被引:39
作者
Liu, Fang [1 ]
Kong, Xinjuan [2 ]
Dou, Qian [2 ]
Ye, Jin [3 ]
Xu, Dong [4 ]
Shang, Haitao [3 ]
Xu, Keshu [3 ]
Song, Yuhu [3 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan 430022, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Coll Med, Dept Gastroenterol, Qingdao 266071, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastroenterol, Wuhan 430022, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Infect Dis, Wuhan 430022, Peoples R China
基金
中国国家自然科学基金;
关键词
CEA; CA19-9; CA15-3; Citology; CARCINOEMBRYONIC ANTIGEN; SEROUS EFFUSIONS; CANCER ANTIGEN-125; ALBUMIN GRADIENT; ADULT PATIENTS; FLUID; CIRRHOSIS; SERUM; MANAGEMENT; ASSAY;
D O I
10.1016/S1665-2681(19)30865-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction. The diagnosis of malignant ascites is a challenging problem in clinical practice, non-invasive techniques should be developed to improve diagnostic accuracy. The diagnostic performances of tumor markers in malignant ascites remained unsettled. Our aim was to evaluate diagnostic performance of tumor markers in differential diagnosis of benign and malignant ascites. Material and methods. A total of 437 patients were enrolled, and the relevant parameters of the patients were analyzed for the differentiation of benign ascites from malignant ascites. Results. At the predetermined cutoff values of tumor makers, tumor markers in ascitic fluid showed better diagnostic performance than those in serum. Combined use of tumor markers and the cytology increased the diagnostic yield of the latter by 37%. In cytologically negative malignant ascites, tumor markers provided assistance in differentiating malignant ascites from benign ascites, and the combination of ascitic tumor markers yielded 86% sensitivity, 97% specificity. Conclusion. Use of a panel of tumor markers exhibited excellent diagnostic performance in diagnosing malignant ascites, which indicated the detection of tumor markers may represent a beneficial adjunct to cytology, thus guiding the selection of patients who might benefit from further invasive procedures.
引用
收藏
页码:357 / 363
页数:7
相关论文
共 26 条
[11]   Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions [J].
Passebosc-Faure, K ;
Li, GR ;
Lambert, C ;
Cottier, M ;
Gentil-Perret, A ;
Fournel, P ;
Pérol, M ;
Genin, C .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :6862-6867
[12]  
Pinto MM, 1996, ACTA CYTOL, V40, P437
[13]   Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 153, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions [J].
Porcel, JM ;
Vives, M ;
Esquerda, A ;
Salud, A ;
Pérez, B ;
Rodríguez-Panadero, F .
CHEST, 2004, 126 (06) :1757-1763
[14]   ASCITIC FLUID ANALYSIS IN MALIGNANCY-RELATED ASCITES [J].
RUNYON, BA ;
HOEFS, JC ;
MORGAN, TR .
HEPATOLOGY, 1988, 8 (05) :1104-1109
[16]   Management of adult patients with ascites due to cirrhosis [J].
Runyon, BA .
HEPATOLOGY, 2004, 39 (03) :841-856
[17]   Management of Adult Patients with Ascites Due to Cirrhosis: An Update [J].
Runyon, Bruce A. .
HEPATOLOGY, 2009, 49 (06) :2087-2107
[18]   Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures [J].
Sangisetty, Suma L. ;
Miner, Thomas J. .
WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2012, 4 (04) :87-95
[19]   Cancer antigen 125: Tumor or serosal marker in case of ascites? [J].
Sevinc, A ;
Sari, R ;
Buyukberber, S .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (20) :2507-2508
[20]   Tumor markers in malignant ascites [J].
Shahab, N .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (08) :949-950